Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-primaquine is the (+)-enantiomer of the 8-aminoquinoline antimalarial drug primaquine. While primaquine is clinically administered as a racemic mixture, the S-enantiomer exhibits distinct pharmacokinetic and toxicological properties. Research indicates that S-primaquine is typically cleared more rapidly than the R-enantiomer and may be more closely associated with the drug's characteristic hemolytic toxicity in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Like the racemate, it is studied for its ability to eliminate hepatic hypnozoites of *Plasmodium vivax* and *Plasmodium ovale* (radical cure) and its gametocytocidal activity against *Plasmodium falciparum*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on s-primaquine.